US 11,851,706 B2
Methods and systems for determining a pregnancy-related state of a subject
Maneesh Jain, South San Francisco, CA (US); Eugeni Namsaraev, South San Francisco, CA (US); Morten Rasmussen, South San Francisco, CA (US); Joan Camunas Soler, South San Francisco, CA (US); Farooq Siddiqui, South San Francisco, CA (US); and Mitsu Reddy, South San Francisco, CA (US)
Assigned to Mirvie, Inc., South San Francisco, CA (US)
Filed by Mirvie, Inc., South San Francisco, CA (US)
Filed on Jul. 29, 2022, as Appl. No. 17/877,106.
Application 17/877,106 is a continuation of application No. 17/522,425, filed on Nov. 9, 2021, granted, now 11,441,183.
Application 17/522,425 is a continuation of application No. 17/060,534, filed on Oct. 1, 2020, granted, now 11,208,693, issued on Dec. 28, 2021.
Application 17/060,534 is a continuation of application No. PCT/US2020/018172, filed on Feb. 13, 2020.
Claims priority of provisional application 62/926,786, filed on Oct. 28, 2019.
Claims priority of provisional application 62/890,248, filed on Aug. 22, 2019.
Claims priority of provisional application 62/805,515, filed on Feb. 14, 2019.
Prior Publication US 2022/0380846 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6876 (2018.01); G16B 40/00 (2019.01); G16B 50/00 (2019.01); C12Q 1/6809 (2018.01); G16B 25/10 (2019.01); G16B 40/20 (2019.01); G16H 50/30 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6883 (2018.01); G16H 10/40 (2018.01)
CPC C12Q 1/6876 (2013.01) [C12Q 1/6809 (2013.01); C12Q 1/6874 (2013.01); C12Q 1/6883 (2013.01); G16B 25/10 (2019.02); G16B 40/00 (2019.02); G16B 40/20 (2019.02); G16B 50/00 (2019.02); G16H 10/40 (2018.01); G16H 50/30 (2018.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01)] 30 Claims
 
1. A method for administering a treatment a pregnant subject to reduce an elevated risk of having a pregnancy complication, comprising:
(a) obtaining a cell-free sample from said pregnant subject, wherein said pregnant subject is asymptomatic for said elevated risk of said pregnancy complication;
(b) assaying proteins or polypeptides obtained from said cell-free sample of said pregnant subject to determine at least one level of at least one pregnancy-associated protein or polypeptide, wherein said at least one pregnancy-associated protein or polypeptide is differentially expressed in a first population of pregnant subjects with a pregnancy involving said pregnancy complication as compared to a second population of pregnant subjects without a pregnancy involving said pregnancy complication;
(c) computer processing said at least one level of said at least one pregnancy-associated protein or polypeptide determined in (b) (i) against at least one reference level of said at least one pregnancy-associated protein or polypeptide or (ii) with a trained machine learning algorithm;
(d) determining, based at least in part on said computer processing in (c), that said pregnant subject has said elevated risk of having said pregnancy complication; and
(e) administering said treatment to said pregnant subject to reduce said elevated risk of having said pregnancy complication, based at least in part on said determining in (d),
wherein said treatment comprises cervical cerclage or a drug selected from the group consisting of a corticosteroid, a progestational agent, insulin, an antibiotic, a tocolytic drug, a calcium channel blocker, a cyclo-oxygenase inhibitor, an oxytocin antagonist, a betamimetic drug, magnesium sulfate, magnesium chloride, and magnesium oxide.